X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (53) 53
humans (48) 48
male (43) 43
female (41) 41
middle aged (35) 35
aged (32) 32
adult (30) 30
oncology (28) 28
aged, 80 and over (26) 26
article (23) 23
cancer (23) 23
surgery (23) 23
prognosis (22) 22
follow-up studies (17) 17
retrospective studies (16) 16
survival rate (16) 16
neoplasm staging (14) 14
young adult (14) 14
analysis (13) 13
medicine & public health (13) 13
survival (13) 13
adolescent (12) 12
prospective studies (11) 11
surgical oncology (11) 11
abridged index medicus (10) 10
immunotherapy (10) 10
treatment outcome (9) 9
tumors (9) 9
recurrence (8) 8
risk factors (8) 8
disease-free survival (7) 7
ipilimumab (7) 7
melanoma (7) 7
metastases (7) 7
metastasis (7) 7
sarcoma (7) 7
adenocarcinoma - pathology (6) 6
antineoplastic agents - therapeutic use (6) 6
carcinoma (6) 6
care and treatment (6) 6
child (6) 6
child, preschool (6) 6
multivariate analysis (6) 6
neoplasm recurrence, local - mortality (6) 6
neoplasm recurrence, local - pathology (6) 6
survival analysis (6) 6
adenocarcinoma (5) 5
gastroenterology and hepatology (5) 5
mortality (5) 5
mutations (5) 5
neoplasm recurrence, local - surgery (5) 5
patients (5) 5
proportional hazards models (5) 5
resection (5) 5
adenocarcinoma - mortality (4) 4
adenocarcinoma - surgery (4) 4
age factors (4) 4
antibodies, monoclonal - therapeutic use (4) 4
chemotherapy (4) 4
combined modality therapy (4) 4
epidemiology (4) 4
health aspects (4) 4
immunohistochemistry (4) 4
immunology (4) 4
infant (4) 4
kaplan-meier estimate (4) 4
melanoma - drug therapy (4) 4
melanoma - immunology (4) 4
melanoma - pathology (4) 4
mutation (4) 4
pathology (4) 4
patient outcomes (4) 4
research (4) 4
risk assessment (4) 4
sarcoma - pathology (4) 4
sarcoma - surgery (4) 4
sex chromosomes (4) 4
13-cis-retinoic acid (3) 3
anti-g (3) 3
antibody (3) 3
antigens (3) 3
biopsy (3) 3
bone neoplasms - secondary (3) 3
cd8 antigen (3) 3
clinical trials (3) 3
competing risk (3) 3
dna sequencing (3) 3
gangliosides - immunology (3) 3
genetics & heredity (3) 3
genomes (3) 3
hematology, oncology and palliative medicine (3) 3
liver neoplasms - secondary (3) 3
liver neoplasms - surgery (3) 3
liver resection (3) 3
lung cancer (3) 3
medical prognosis (3) 3
melanoma - mortality (3) 3
metastatic melanoma (3) 3
minimal residual disease (3) 3
monoclonal antibodies (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 05/2017, Volume 545, Issue 7652, pp. 60 - 65
Despite the success of monotherapies based on blockade of programmed cell death 1 (PD-1) in human melanoma, most patients do not experience durable clinical... 
CRITERIA | MELANOMA | PEMBROLIZUMAB | IMMUNE CHECKPOINT BLOCKADE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | BRAF INHIBITORS | CHRONIC VIRAL-INFECTION | CANCER-THERAPY | IPILIMUMAB | EXHAUSTION | CD8-Positive T-Lymphocytes - cytology | Antibodies, Monoclonal, Humanized - therapeutic use | Melanoma - blood supply | Humans | Ki-67 Antigen - metabolism | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Treatment Outcome | Melanoma - pathology | Phenotype | Antibodies, Monoclonal, Humanized - administration & dosage | Ki-67 Antigen - immunology | Antibodies, Monoclonal, Humanized - pharmacokinetics | Melanoma - immunology | Melanoma - drug therapy | CD8-Positive T-Lymphocytes - metabolism | Female | Programmed Cell Death 1 Receptor - immunology | Antibodies, Monoclonal, Humanized - immunology | CD8-Positive T-Lymphocytes - immunology | Neoplasm Staging | Tumor Burden - immunology | Oncology, Experimental | Melanoma | Physiological aspects | Research | T cells | Tumors | Apoptosis | Cancer | Profiling | PD-1 protein | CD8 antigen | Medical services | Clinical trials | Lymphocytes T | Blood | Metastases | Immunology | Lymphocytes | Immunotherapy | Peripheral blood | Pretreatment | Medical research | Immunoglobulins | T cell receptors | Pharmacology | Patients | Pathology | Cell death | PD-L1 protein | Infiltration
Journal Article
Journal Article
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2014, Volume 135, Issue 9, pp. 2199 - 2205
Anti‐GD2 murine antibody 3F8 plus subcutaneously (sc) administered granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) was used against primary... 
myeloid effectors | FCGR2A polymorphism | immunotherapy | Viral antibodies | Analysis | Antibodies | Macrophage colony stimulating factor | Neuroblastoma | Macrophages | Gangliosides | Immunoglobulins | Immunotherapy | Cells | Cancer
Journal Article
BJU International, ISSN 1464-4096, 12/2012, Volume 110, Issue 11, pp. 1696 - 1701
Journal Article
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 11/2019, Volume 125, Issue 22, pp. 4019 - 4032
Background Despite the rapid adoption of immunotherapies in advanced non–small cell lung cancer (advNSCLC), knowledge gaps remain about their real‐world (rw)... 
non–small cell lung cancer | real‐world | endpoints | PD‐1 | immunotherapy | PD‐L1 | Correlation | Inhibitors | Cell survival | Small cell lung carcinoma | Immunotherapy | Lung cancer | Clinical trials | Staining | Survival | Patients | Electronic medical records | Electronic health records
Journal Article
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 5/2017, Volume 24, Issue 5, pp. 1358 - 1366
Journal Article